Filing Flows › Bioventus (BVS) › Q1 2025
Bioventus (BVS) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 6, 2025
Bioventus (BVS) reported revenue of $124M for the first quarter 2025 (Q1 2025), -4% from a year earlier and -19% from the quarter before. Operating margin was 3.9%, net loss $3.3M (2.7% of revenue).
Bioventus, Q1 2025: revenue $124M (-4% year over year), operating margin 3.9%, net loss $3.3M, operating cash flow −$19.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $124M | -19% | -4% |
| Operating profit | $4.9M | — | — |
| Net earnings | −$3.3M | — | — |
| Operating cash flow | −$19.3M | — | — |
What changed
Revenue was $123.9M in Q1 2025, down 4% year over year and down 19% from the previous quarter.
Gross margin was 67.0%, down 1.2 points from a year earlier. Operating profit was $4.9M, a 3.9% margin (up 0.1 points year over year). Operating expenses fell 6% while revenue fell 4%. The fastest-growing cost line was Research & development (+15%). The quarter ended with a net loss of $3.3M, wider than the previous quarter's $318K loss. Minority interests bore $685K of it: to shareholders the quarter was a loss of $2.6M. Net interest and other expense of $8.3M was the main reason.
Operating cash flow was −$19.3M. Non-cash charges added back $11.9M of depreciation and amortization and $2.4M of share-based compensation. Working capital and other items used $30.3M. Capital expenditures of $826K exceeded it, leaving free cash flow of −$20.2M.
Questions
What was Bioventus' revenue in the first quarter 2025?
Bioventus (BVS) reported revenue of $124M for the first quarter 2025 (Q1 2025), -4% from a year earlier and -19% from the quarter before.
Was Bioventus profitable in the first quarter 2025?
Operating profit was $4.9M (3.9% of revenue) and net loss $3.3M.
Source: Bioventus 10-Q on SEC EDGAR.